Advanced Search

Journal of Traditional Chinese Medicine >

2024 , Vol. 44 >Issue 6: 1217 - 1226

DOI: https://doi.org/10.19852/j.cnki.jtcm.20240409.001

Research Articles

Bailing capsule (百令胶囊) alleviates autoimmune thyroiditis via regulating peroxisome proliferator-activated receptor signaling pathway: a multi-omics analysis

  • Qixin WANG ,
  • Liting XU ,
  • Jiangpeng WU ,
  • Xueling HE ,
  • Huan TANG ,
  • Guangqing CHENG ,
  • Tianming LU ,
  • Chuanhao DAI ,
  • Qiuyan GUO ,
  • Jigang WANG
Expand
  • 1 State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China
    2 School of Chinese Materia Medica, and State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

Received date: 2023-11-19

  Accepted date: 2024-03-11

  Online published: 2024-04-09

Supported by

Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine: Studies on the Antimalarial and Drug Resistance Mechanisms of Artemisinin and the Expansion of New Indicationsptor Containing Pyrin Domain 3 Inflammasome to Explore the Mechanism of Bufei Huoxue Capsule on Pulmonary Fibrosis in Silicosis(ZYYCXTD-C-202002)

Fold

Abstract

OBJECTIVE: To investigate the efficacy and potential mechanism of Bailing capsule (百令胶囊, BL) anti-autoimmune thyroiditis (AIT).

METHODS: Based on the AIT rat model, the effect of BL in alleviating AIT was evaluated by detecting serum thyroid index free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), thyroglobulin antibody (TGAb), thyroid peroxidase antibody (TPOAb), and inflammatory factors Interferon-gamma (IFN-γ), Interleukin-4, -10, and -12 (IL-4, IL-10, and IL-12) as well as thyroid tissue Hematoxylin-eosin (HE) staining and ultrastructure observation. The mechanism of BL was explored by combining transcriptome and proteome analysis, and further verified by Western blot (WB).

RESULTS: BL effectively reduced serum FT3, FT4, TGAb, and TPOAb levels in AIT rats, restored TSH balance, inhibited the release of pro-inflammatory cytokines IFN-γ and IL-12, promoted the production of anti-inflammatory cytokines IL-4 and IL-10, and significantly reduced IFN-γ/IL-4 and IL-12/IL-10, improved thyroid follicular structure, and protected thyroid tissue from injury. Kyoto Encyclopedia of Genes and Genomes and protein interaction network analysis showed that BL affected the expression of fatty acid-binding protein 4, acyl-CoA synthetase long-chain family member 1, and acyl-CoA dehydrogenase long chain to regulate the peroxisome proliferator-activated receptor signaling pathway, thereby inhibiting the fatty acid metabolism and the inflammatory state of AIT rats.

CONCLUSIONS: BL could effectively reduce thyroid inflammation in AIT model rats. The possible BL mechanism was to regulate the peroxisome proliferator-activated receptor signaling pathway and inhibit fatty acid metabolism. This study suggested that BL has the potential to be used in clinical treatment of AIT.

Key words： thyroiditis, autoimmune; cordyceps; fatty acid; peroxisome proliferator-activated receptors; Bailing capsule

Cite this article

Qixin WANG , Liting XU , Jiangpeng WU , Xueling HE , Huan TANG , Guangqing CHENG , Tianming LU , Chuanhao DAI , Qiuyan GUO , Jigang WANG . Bailing capsule (百令胶囊) alleviates autoimmune thyroiditis via regulating peroxisome proliferator-activated receptor signaling pathway: a multi-omics analysis[J]. Journal of Traditional Chinese Medicine, 2024 , 44(6) : 1217 -1226 . DOI: 10.19852/j.cnki.jtcm.20240409.001

References

1. Mincer DL, Jialal I. Hashimoto thyroiditis. Mather: In StatPearls, 2023: 1.
2. Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev 2014; 13: 391-7.
3. Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol 2018; 14: 301-16.
4. Wang YZ, Zhang YY, Qiao JJ, Lu YY, Xia ZY. Protective effect of thyroid and restores of ovarian function of Buzhong Yiqi granule on experimental autoimmune thyroiditis in female rats. J Tradit Chin Med 2024; 44: 315-323.
5. Xu J, Yuan Q, Wu K, et al. Effects of Bailing capsule on diabetic nephropathy based on UPLC-MS urine metabolomics. RSC Adv 2019; 9: 35969-75.
6. Shashidhar MG, Giridhar P, Udaya Sankar K, et al. Bioactive principles from Cordyceps sinensis: a potent food supplement - a review. J Funct Foods 2013; 5: 1013-30.
7. Zhou X, Gong Z, Su Y, et al. Cordyceps fungi: natural products, pharmacological functions and developmental products. J Pharm Pharmacol 2009; 61: 279-91.
8. Zhang H, Li Y, Mi J, et al. GC-MS profiling of volatile components in different fermentation products of Cordyceps sinensis mycelia. Molecules 2017; 22: 1800.
9. Tian YY, Wang N, Hu JZ. Clinical observation on Bailing capsule in treatment of Hashimoto's thyroiditis. Shi Yong Zhong Yi Nei Ke Za Zhi 2020; 34: 75-8.
10. Xue YH, Li CX, Shang J, et al. Effect of Bailing capsule on Hashimoto's thyroiditis. Shenzhen Zhong Xi Yi Jie He Za Zhi 2021; 31: 62-4.
11. Yang ZY. Effects of Bailing capsules combined with Levothyroxine sodium in treatment autoimmune thyroiditis. Zhong Guo Min Kang Yi Xue 2022; 34: 24-7.
12. Burek CL, Talor MV. Environmental triggers of autoimmune thyroiditis. J Autoimmun 2009; 33: 183-9.
13. Zhang C, Qin L, Sun B, et al. Transcriptome analysis of the effect of diosgenin on autoimmune thyroiditis in a rat model. Sci Rep 2021; 11: 6401.
14. Zhang Q, Xiao X, Li M, et al. Bailing capsule (Cordyceps sinensis) ameliorates renal triglyceride accumulation through the PPARα pathway in diabetic rats. Front Pharmacol 2022; 13: 915592.
15. Zhao C, Yang D, Pang W. Immunomodulatory effect of Bailing capsule on thyroid follicular carcinoma in mice. Zhong Guo Yao Shi 2011; 14: 94-5.
16. Ragusa F, Fallahi P, Elia G, et al. Hashimotos' thyroiditis: epidemiology, pathogenesis, clinic and therapy. Best Pract Res Clin Endocrinol Metab 2019; 33: 101367.
17. Wang S, Liu Y, Zhao N, et al. IL-34 expression is reduced in Hashimoto's thyroiditis and associated with thyrocyte apoptosis. Front Endocrinol (Lausanne) 2018; 9: 629.
18. Kunadirek P, Pinjaroen N, Nookaew I, et al. Transcriptomic analyses reveal long non-coding RNA in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma. Int J Mol Sci 2022; 23: 7882.
19. Song XH, Zan RZ, Yu CH, et al. Effects of modified Haizao Yuhu decoction in experimental autoimmune thyroiditis rats. J Ethnopharmacol 2011; 135: 321-4.
20. Miko? H, Miko? M, Obara-Moszyńska M, et al. The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). Endokrynol Pol 2014; 65: 150-5.
21. Chao G, Zhu Y, Fang L. Correlation between Hashimoto's thyroiditis-related thyroid hormone levels and 25-hydroxyvitamin D. Front Endocrinol (Lausanne) 2020; 11: 4.
22. Pyzik A, Grywalska E, Matyjaszek-Matuszek B, et al. Immune disorders in Hashimoto's thyroiditis: what do we know so far? J Immunol Res 2015; 2015: 979167.
23. Rydzewska M, Jaromin M, Pasierowska IE, et al. Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases. Thyroid Res 2018; 11: 2.
24. Su XL, Zhang T, Guo S, et al. Efficacy of Wumei Baijiang prescription on regulatory T cells / helper T cells Immune balance in mice with ulcerative coliti. J Tradit Chin Med 2022; 42: 30-38.
25. Ajjan RA, Watson PF, McIntosh RS, et al. Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. Clin Exp Immunol 1996; 105: 523-8.
26. Martinenaite E, Ahmad SM, Bendtsen SK, et al. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope. Cancer Immunol Immunother 2019; 68: 1901-7.
27. Dienz O, Eaton SM, Bond JP, et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med 2009; 206: 69-78.
28. Raphael I, Nalawade S, Eagar TN, et al. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 2015; 74: 5-17.
29. Ganesh BB, Bhattacharya P, Gopisetty A, et al. Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity. J Interferon Cytokine Res 2011; 31: 721-31.
30. Shearer BG, Billin AN. The next generation of PPAR drugs: do we have the tools to find them? Biochim Biophys Acta 2007; 1771: 1082-93.
31. Michalik L, Wahli W. Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Curr Opin Biotechnol 1999; 10: 564-70.
32. Zhang JM, Liang SL, Nie P, et al. Efficacy of Kushen decoction on high-fat-diet-induced hyperlipidemia in rats. J Tradit Chin Med 2022; 42: 364-71.
33. Blanquart C, Barbier O, Fruchart JC, et al. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 2003; 85: 267-73.
34. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 2004; 4: 61-70.
35. Diab A, Deng C, Smith JD, et al. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta (12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002; 168: 2508-15.
36. Karger S, Berger K, Eszlinger M, et al. Evaluation of peroxisome proliferator-activated receptor-gamma expression in benign and malignant thyroid pathologies. Thyroid 2005; 15: 997-1003.
37. Au AY, McBride C, Wilhelm KG Jr, et al. PAX8-peroxisome proliferator-activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth. Endocrinology 2006; 147: 367-76.
38. Marx N, Mach F, Sauty A, et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000; 164: 6503-8.
39. Werion A, Joris V, Hepp M, et al. Pioglitazone, a PPARγ agonist, upregulates the expression of caveolin-1 and catalase, essential for thyroid cell homeostasis: a clue to the pathogenesis of Hashimoto's thyroiditis. Thyroid 2016; 26: 1320-31.
40. Antonelli A, Ferrari SM, Mancusi C, et al. Interferon-α, -β and -γ induce CXCL11 secretion in human thyrocytes: modulation by peroxisome proliferator-activated receptor γ agonists. Immunobiology 2013; 218: 690-5.
41. Fallahi P, Ferrari SM, Corrado A, et al. Targeting chemokine (C-X-C motif) receptor 3 in thyroid autoimmunity. Recent Pat Endocr Metab Immune Drug Discov 2014; 8: 95-101.
42. Montaigne D, Butruille L, Staels B. PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol 2021; 18: 809-23.
43. Chen Q, Zhao JJ, Zheng DM, et al. The relationship between thyroid function and lipid metabolism: a clinical analysis. Jun Shi Yi Xue Ke Xue Yuan Yuan Kan 2010; 34: 364-6.
44. Chen CM, Liu J, Jia YM, et al. Correlation between serum thyroid-stimulating hormone and blood lipid in subjects with normal thyroid function. Zhong Guo Xin Xue Guan Za Zhi 2020; 25: 45-9.
45. Yu HY, Zhang MX, Cianflone K, et al. Influence of thyroid diseases on human serum adipocytokines. Hua Zhong Ke Ji Da Xue Xue Bao 2005; 34: 3.
46. Wang F, Tan Y, Wang C, et al. Thyroid-stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormones. J Clin Endocrinol Metab 2012; 97: 2724-31.
47. Lo MC, Lu CI, Chen MH, et al. Glycoxidative stress-induced mitophagy modulates mitochondrial fates. Ann N Y Acad Sci 2010; 1215: 1-7.
Options
Outlines

/

〈 〉